+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism Of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast to 2030- Product Image
Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism Of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast to 2030- Product Image
Sale

Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism Of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083023
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Small molecule therapeutics are reshaping treatment options across the inflammatory bowel disease (IBD) landscape, unlocking new pathways for improved clinical outcomes and operational agility. Leading stakeholders are capitalizing on recent advances in drug design, precision targeting, and regulatory approval frameworks to pursue more patient-centric and commercially viable solutions. The market is evolving swiftly, fueled by innovation, shifting trade policies, and a diversified competitive environment.

Market Snapshot: Small Molecule Therapeutic Revolution for IBD

The small molecule IBD therapeutics market is experiencing robust expansion, highlighted by notable growth in both Crohn’s disease and ulcerative colitis therapy fields. This progression is propelled by the rising need for more accessible oral alternatives to traditional biologics, a strong pipeline of next-generation compounds, and increasing adoption in key healthcare regions. Industry participants are responding to demand for targeted interventions, simplified administration, and cost-effectiveness as payers and providers focus on balancing efficacy with long-term economic sustainability.

Scope & Segmentation of the Small Molecule IBD Market

  • Indications Covered:
    • Crohn’s Disease: Addressing mild, moderate, and severe stages
    • Ulcerative Colitis: Focused on mild, moderate, and severe cases
  • Mechanisms of Action:
    • JAK Inhibitors, including both JAK1-selective and Pan-JAK compounds
    • PDE4 Inhibitors
    • S1P Receptor Modulators: Involving S1P1 and S1P1/5 targeting
  • Distribution Channels: Hospital, Retail, and Online Pharmacy settings for outpatient, inpatient, and long-term adherence needs
  • Treatment Types: Induction therapies for remission and maintenance regimens for ongoing disease control
  • Therapy Lines: Encompassing first, second, and third-line uses and beyond
  • Development Stages: Commercially approved products, along with clinical phase II and III pipeline candidates
  • Regions Analyzed: Americas (including specific U.S. states), Europe, Middle East & Africa, and Asia-Pacific countries
  • Key Companies Profiled: Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Arena Pharmaceuticals, Galapagos NV

Key Takeaways on Small Molecule IBD Therapies

  • Recent innovations, particularly in Janus kinase inhibition and sphingosine-1-phosphate modulation, are broadening therapeutic choices and supporting the shift toward precision medicine for IBD.
  • Adaptive regulatory strategies now allow more rapid entry of novel mechanisms, provided they meet stringent safety and efficacy benchmarks; this is accelerating therapeutic availability across priority regions.
  • Real-world evidence and digital health tools are strengthening post-market validation, enhancing stakeholder confidence and enabling ongoing refinement of dosing strategies.
  • Distinctive market segmentation is optimizing investment by focusing on diverse indications, molecular pathways, and therapy lines, ensuring targeted approaches for each patient population.
  • Strategic partnerships—including collaborations between large multinationals, mid-sized firms, and emerging biotechs—are fostering portfolio diversification and facilitating cross-regional commercialization.

Tariff Impact: Navigating U.S. Trade Policy Shifts

The introduction of updated U.S. tariffs in 2025 created complex cost pressures for manufacturers and distributors of small molecule IBD therapies. Industry players recalibrated sourcing and manufacturing strategies, increased geographic diversification, and pursued long-term supplier agreements for cost control. In response to payer demands, pharmacoeconomic justifications and real-world performance data became critical tools for formulary positioning. Enhanced collaboration with contract manufacturing partners in tariff-favored regions also contributed to industry resilience amid regulatory fluctuation.

Methodology & Data Sources

This analysis is based on comprehensive secondary research—spanning peer-reviewed literature, regulatory filings, and clinical trial registries—built on validated insights from proprietary databases. Primary research contributed qualitative perspectives via structured interviews with clinical, payer, and regulatory stakeholders; triangulation methods ensured reliability and fidelity across all data points.

Why This Report Matters: Strategic Value for Decision-Makers

  • Leverages in-depth segmentation to support optimized product positioning, market access, and resource allocation strategies specific to small molecule IBD therapies.
  • Highlights actionable trends—including regional market entry dynamics, regulatory developments, and partnership opportunities—relevant to executive planning and innovation roadmaps.
  • Equips leaders with evidence-based insight into tariff impacts, channel shifts, and clinical pipeline differentiators essential for sustained growth.

Conclusion

The future of IBD therapy hinges on continued small molecule innovation, responsive supply chains, and data-driven engagement with key stakeholders. This report enables industry leaders to navigate the evolving market landscape and capture new growth opportunities with greater precision.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Indication
8.1. Introduction
8.2. Crohn Disease
8.2.1. Mild
8.2.2. Moderate
8.2.3. Severe
8.3. Ulcerative Colitis
8.3.1. Mild
8.3.2. Moderate
8.3.3. Severe
9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Mechanism Of Action
9.1. Introduction
9.2. JAK Inhibitors
9.2.1. JAK1 Selective Inhibitors
9.2.2. Pan JAK Inhibitors
9.3. PDE4 Inhibitors
9.4. S1P Receptor Modulators
9.4.1. S1P1 Modulators
9.4.2. S1P1/5 Modulators
10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Treatment Type
11.1. Introduction
11.2. Induction Therapy
11.3. Maintenance Therapy
12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line And Beyond
13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Development Stage
13.1. Introduction
13.2. Approved
13.3. Clinical Phase II
13.4. Clinical Phase III
14. Americas Small Molecules Drugs for Inflammatory Bowel Diseases Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. AbbVie Inc.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Gilead Sciences, Inc.
17.3.5. Arena Pharmaceuticals, Inc.
17.3.6. Galapagos NV
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET MULTI-CURRENCY
FIGURE 2. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 66. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 67. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 70. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 73. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 134. GERMANY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 138. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 139. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 144. FRANCE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 155. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 157. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 158. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 161. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 164. ITALY SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 174. SPAIN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 208. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 209. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 225. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 227. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 228. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 229. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 231. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 234. QATAR SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 237. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 238. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Small Molecules Drugs for Inflammatory Bowel Diseases market report include:
  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Arena Pharmaceuticals, Inc.
  • Galapagos NV

Related Topics

Related Reports

Inflammatory Bowel Disease - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Inflammatory Bowel Disease - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 146 Pages
  • Global
From
Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 170 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel, Type, and Country-Level Analysis - Analysis and Forecast, 2025-2035 - Product Image

Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel, Type, and Country-Level Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.